Salud financiera de hoja de balance de Beta Drugs
Salud financiera controles de criterios 6/6
Beta Drugs tiene un patrimonio de accionistas total de ₹1.8B y una deuda total de ₹190.6M, lo que sitúa su ratio deuda-patrimonio en 10.5%. Sus activos y pasivos totales son ₹2.9B y ₹1.1B respectivamente. El BAIT de Beta Drugs es de ₹558.1M, por lo que su ratio de cobertura de intereses es de 27.2. Tiene efectivo e inversiones a corto plazo que ascienden a ₹278.9M.
Información clave
10.5%
Ratio deuda-patrimonio
₹190.60m
Deuda
| Ratio de cobertura de intereses | 27.2x |
| Efectivo | ₹278.87m |
| Patrimonio | ₹1.81b |
| Total pasivo | ₹1.14b |
| Activos totales | ₹2.95b |
Actualizaciones recientes sobre salud financiera
These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29
Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Recent updates
Why Investors Shouldn't Be Surprised By Beta Drugs Limited's (NSE:BETA) 30% Share Price Surge
Nov 08Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Aug 30Investors Appear Satisfied With Beta Drugs Limited's (NSE:BETA) Prospects As Shares Rocket 27%
Aug 30Earnings Tell The Story For Beta Drugs Limited (NSE:BETA) As Its Stock Soars 29%
Dec 23Does Beta Drugs (NSE:BETA) Deserve A Spot On Your Watchlist?
Dec 11These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Jul 29Here's Why We Think Beta Drugs (NSE:BETA) Is Well Worth Watching
Jun 17Here's Why I Think Beta Drugs (NSE:BETA) Might Deserve Your Attention Today
Feb 21Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
Dec 20With EPS Growth And More, Beta Drugs (NSE:BETA) Is Interesting
Nov 21These 4 Measures Indicate That Beta Drugs (NSE:BETA) Is Using Debt Reasonably Well
Sep 02Beta Drugs (NSE:BETA) Seems To Use Debt Quite Sensibly
May 20Is Beta Drugs (NSE:BETA) A Risky Investment?
Jan 29Is Beta Drugs Limited's (NSE:BETA) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?
Dec 25Chairman & MD Vijay Batra Just Bought A Handful Of Shares In Beta Drugs Limited (NSE:BETA)
Nov 20
Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹2.1B) de BETA superan a sus pasivos a corto plazo (₹972.5M).
Pasivo a largo plazo: Los activos a corto plazo de BETA (₹2.1B) superan a sus pasivos a largo plazo (₹164.0M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: BETA tiene más efectivo que su deuda total.
Reducción de la deuda: El ratio deuda-patrimonio de BETA ha pasado de 32.5% a 10.5% en los últimos 5 años.
Cobertura de la deuda: La deuda de BETA está bien cubierta por el flujo de caja operativo (132.1%).
Cobertura de intereses: Los pagos de intereses de la deuda de BETA están bien cubiertos por el BAIT (27.2x cobertura).